This clinical trial is focused on studying the effects of a medication called tranexamic acid in patients undergoing total hip replacement surgery. The main goal is to see how different doses of this medication can help reduce the loss of hemoglobin, which is a protein in red blood cells that carries oxygen, during and after the surgery. The study is designed to be a randomized and double-blind trial, meaning neither the patients nor the researchers know who is receiving the actual medication or a placebo, to ensure unbiased results.
Participants in the study will receive tranexamic acid through an infusion, which is a method of delivering medication directly into the bloodstream. The study will also involve the use of sodium chloride solution, commonly known as saline, which is often used in medical settings to provide hydration and as a vehicle for other medications. Additionally, some participants may receive apixaban, a medication that helps prevent blood clots, taken orally in the form of a tablet.
The study will monitor the participants’ hemoglobin levels before the surgery and on the eighth day after the surgery to measure any changes. It will also look at the concentration of tranexamic acid in the blood and other factors like the need for blood transfusions and the occurrence of any blood clots or other serious events. The study aims to provide valuable information on how to best use tranexamic acid to improve outcomes for patients undergoing hip replacement surgery.
France 
